Literature DB >> 15578948

Ribozyme- and deoxyribozyme-strategies for medical applications.

S Schubert1, J Kurreck.   

Abstract

Ribozymes are catalytically active nucleic acids capable of site-specific cleavage of target mRNAs. They have widely been employed as tools in functional studies and for therapeutic purposes. Different classes of ribozymes distinguished by size and mechanism of action have been discovered in natural systems or obtained by in vitro selection. After an introduction to different types of ribozymes with a special focus on the hammerhead and hairpin ribozyme, major challenges in the process of developing ribozymes for medical purposes will be described in the present review. Subsequently, examples of ribozyme applications in animal models for various diseases including cancer, viral infections, rheumatoid arthritis and cardiovascular diseases will be given. The course of phase I and II clinical trials with ribozymes designed to treat patients with virus infections or cancer will be outlined. Finally, the current significance of ribozymes will be discussed in the light of the emergence of new powerful anti-mRNA strategies, particularly RNA interference (RNAi).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15578948     DOI: 10.2174/1389450043345092

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  24 in total

Review 1.  Gene therapeutic approaches to inhibit hepatitis B virus replication.

Authors:  Maren Gebbing; Thorsten Bergmann; Eric Schulz; Anja Ehrhardt
Journal:  World J Hepatol       Date:  2015-02-27

2.  Gene targeting in the Gram-Positive bacterium Lactococcus lactis, using various delta ribozymes.

Authors:  Karine Fiola; Jean-Pierre Perreault; Benoit Cousineau
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

3.  Inhibition of hepatitis C IRES-mediated gene expression by 8-17 deoxyribozymes in human tissue culture cells.

Authors:  A V Vlassov; H Ilves; B H Johnston
Journal:  Dokl Biochem Biophys       Date:  2006 Sep-Oct       Impact factor: 0.788

Review 4.  Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies.

Authors:  Ravinay Bhindi; Roger G Fahmy; Harry C Lowe; Colin N Chesterman; Crispin R Dass; Murray J Cairns; Edward G Saravolac; Lun-Quan Sun; Levon M Khachigian
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

Review 5.  The structural stability and catalytic activity of DNA and RNA oligonucleotides in the presence of organic solvents.

Authors:  Shu-Ichi Nakano; Naoki Sugimoto
Journal:  Biophys Rev       Date:  2016-01-11

Review 6.  Silencing human genetic diseases with oligonucleotide-based therapies.

Authors:  Tamara Martínez; Natalia Wright; Marta López-Fraga; Ana Isabel Jiménez; Covadonga Pañeda
Journal:  Hum Genet       Date:  2013-03-14       Impact factor: 4.132

7.  RNA-cleaving deoxyribozyme sensor for nucleic acid analysis: the limit of detection.

Authors:  Yulia V Gerasimova; Evan Cornett; Dmitry M Kolpashchikov
Journal:  Chembiochem       Date:  2010-04-12       Impact factor: 3.164

8.  Inhibition of HIV-1 Integrase gene expression by 10-23 DNAzyme.

Authors:  Nirpendra Singh; Atul Ranjan; Souvik Sur; Ramesh Chandra; Vibha Tandon
Journal:  J Biosci       Date:  2012-07       Impact factor: 1.826

9.  The distribution, clearance, and safety of an anti-MMP-9 DNAzyme in normal and MMTV-PyMT transgenic mice.

Authors:  Miranda A Hallett; Pooja Dalal; Trevor W Sweatman; Tayebeh Pourmotabbed
Journal:  Nucleic Acid Ther       Date:  2013-10-01       Impact factor: 5.486

10.  Selection of the most potent specific on/off adaptor-hepatitis delta virus ribozymes for use in gene targeting.

Authors:  Michel V Lévesque; Samuel G Rouleau; Jean-Pierre Perreault
Journal:  Nucleic Acid Ther       Date:  2011-07-08       Impact factor: 5.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.